Genmab A/S
Toldbodgade 33
Copenhagen
K-1253
Tel: 45-7020-2728
Fax: 45-7020-2729
Website: http://www.genmab.com/
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.YEAR FOUNDED:
February 1999
LEADERSHIP:
CEO and Founder: Jan G. J. van de Winkel, Ph.D.
CFO: David Eatwell
JOBS: Please click here for Genmab job opportunities.
CLINICAL TRIAL
Please click here for clinical trial information.
PRODUCTS:
All Products
FOLLOW GENMAB: Tweets by Genmab
377 articles with Genmab A/S
-
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
6/22/2021
Genmab A/S (Nasdaq:GMAB)announced today that the European Commission (EC) has granted marketing authorization for the daratumumab subcutaneous (SC) formulation(daratumumab and hyaluronidase-fihj), known as DARZALEX® SCin the European Union, in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) for the treatment of adult patients with newly diagnosed systemiclight-chain (AL) amyloidosis.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
6/2/2021
Genmab A/S and Bolt Biotherapeutics, Inc. announced that the companies have entered into an oncology research and development collaboration.
-
Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
5/21/2021
Company Announcement Janssen received a positive CHMP opinion for DARZALEX ® SC (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed systemic light-chain (AL) amyloidosis Opinion based on data from the Phase 3 ANDROMEDA (AMY3001) study CHMP also issued a positive opinion recommending DARZALEX ®
-
Genmab Announces Financial Results for the First Quarter of 2021
5/5/2021
Genmab Interim Report for the First Quarter Ended March 31,2021
-
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
4/9/2021
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
-
Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
2/10/2021
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for tisotumab vedotin.
-
Clinical Catch-Up: November 23-27
11/30/2020
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look. -
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
-
Clinical Catch-Up: October 19-23
10/26/2020
It was another busy week for clinical trial updates and news. Here’s a look. -
The study is evaluating daratumumab monotherapy as maintenance treatment compared to observation, in other words, no treatment, for patients with newly diagnosed multiple myeloma that are eligible for autologous stem cell transplant.
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
In a brief statement, Genmab said it initiated binding arbitration related to two matters under its Darzalex (daratumumab) license agreement with Janssen Biotech.
-
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
9/21/2020
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 - Data Featured in Late-Breaking Proffered Paper Oral Presentation - - Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA - BOTHELL, Wash. & COPENHAGEN, Denmark--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) an
-
AbbVie and Genmab Announce Broad Oncology Collaboration
6/10/2020
AbbVie and Genmab entered into a broad collaboration to jointly develop and commercialize three of Genmab's next-generation bispecific antibody products, including epcoritamab
-
The collaboration will focus on the development of three of Genmab's bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.
-
Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets
5/25/2020
Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's DuoBody® technology platform against disease relevant target antigens.
-
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
-
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
12/19/2019
Genmab A/S (Nasdaq: GMAB) and CureVac AG announced today that Genmab and CureVac have entered into a research collaboration and license agreement.
-
Genmab Announces Financial Results for the First Nine Months of 2019
11/6/2019
Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs